Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study

202032 citationsJournal Articlehybrid Open Access

Authors

Joshua J. McFarlane · Virginia Cancer Institute

Mark D. Kochenderfer · Mountain Blue Cancer Care Center

Mark R. Olsen · Oklahoma Cancer Specialists and Research Institute

Todd M. Bauer · Tennessee Oncology

Ana M. Molina · Cornell University

Ralph J. Hauke · Nebraska Cancer Specialists

James A. Reeves

Abstract

This study validates the safety and efficacy of nivolumab 240 mg Q2W flat-dose monotherapy for previously treated advanced ccRCC and adds to previous safety and efficacy data using the 3 mg/kg Q2W dose.

Topics & Keywords

Renal cell carcinoma treatment Cancer Immunotherapy and Biomarkers Bladder and Urothelial Cancer Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Genitourinary Cancer

Volume 18, Issue 6, pp. 469-476.e4

DOI: 10.1016/j.clgc.2020.06.002

Field-Weighted Citation Impact: 2.65